Brochitol has CHMP recommendation for treatment of Cystic Fibrosis

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bronchitol ( inhaled mannitol) from Pharmaxis, an Australian pharmaceutical company, for the treatment of Cystic Fibrosis. The drug is an inhaled dry powder formulation of mannitol and is intended to reduce the amount of mucus in the lungs of patients suffering from chronic respiratory syndromes. Pharmaxis have agreed that Quintiles will market the drug in Western Europe. Bronchitol is already approved in Australia. The recommendation comes after the CHMP rejected the drug in June amid safety concerns about its use in children with CF